Literature DB >> 16969289

Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.

Marc Hazzan1, David Buob, Myriam Labalette, François Provot, François Glowacki, Maxime Hoffmann, Marie-Christine Copin, Christian Noel.   

Abstract

BACKGROUND: We report the two-year follow-up of a trial comparing the three-month postgraft discontinuation of either cyclosporine (CsA) or mycophenolate mofetil (MMF) from a triple-drug regimen after de novo renal transplantation.
METHODS: One hundred and eight patients were enrolled in this study and randomized to be withdrawn from CsA (MMF group, n=54) or MMF (CsA group, n=54).
RESULTS: Despite an increased risk of acute rejection and a lower, but nonsignificant, two-year graft survival, CsA withdrawal induced a sustained improvement of the renal function. At one year, the chronic allograft damage index was similar in both the MMF and CsA groups. However, CsA elimination resulted in a higher incidence of C4d deposits, irrespective of the occurrence of a prior acute rejection. While this finding could suggest a risk of chronic rejection in the MMF group, the outcome did not appear to be related to the C4d status. Moreover, logistic regression analysis showed that only two factors, acute rejection and the one-year glomerular filtration rate level, were predictive of a significant decline of the renal function at two years.
CONCLUSIONS: These results point out the need to secure the minimization of the calcineurin inhibitors after renal transplantation, in order to reduce the risk of acute rejection in these patients, because this strategy allows the improvement of the one-year renal function which is predictive of a chronic allograft dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969289     DOI: 10.1097/01.tp.0000229424.11872.a0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

2.  Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients.

Authors:  Marc Hazzan; Alexandre Hertig; David Buob; Marie-Christine Copin; Christian Noël; Eric Rondeau; Yi-Chun Dubois-Xu
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

3.  An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.

Authors:  Mark LaSpina; Sudipta Tripathi; Louis A Gatto; David Bruch; Kristopher G Maier; Dilip S Kittur
Journal:  J Surg Res       Date:  2008-01-29       Impact factor: 2.192

4.  Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation.

Authors:  M Wagner; E M Balk; D M Kent; B L Kasiske; H Ekberg
Journal:  Am J Transplant       Date:  2009-10       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.